In our next step, our lipid profiling in the NAFLD group identified a decrease of plasmalogens in patients with the GG-genotype of PNPLA3, compared to those with the CC- and CG-genotypes. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.